Advertisements

Guaifenesin DM Elixir

Quick links to important sections

Guaifenesin DM Elixir

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Guaifenesin DM Elixir

Property Description
Active Ingredients Dextromethorphan (Cough Suppressant), Guaifenesin (Expectorant)
Form Elixir (Oral Solution)
Pharmacological Class Non-narcotic Antitussive and Expectorant Combination
Common Use Symptomatic relief of cough and thick chest mucus
Origin Synthetic and Synthetic Derivative

Guaifenesin DM Elixir: A Combination Antitussive and Expectorant

Guaifenesin DM Elixir is defined as a combination product, a liquid medicine incorporating the two active ingredients, Dextromethorphan and Guaifenesin, to address two major symptoms of acute respiratory discomfort simultaneously. This pharmaceutical preparation is classified as an upper respiratory combination product, which is widely available over-the-counter (OTC) under numerous generic and commercial formulations. The dual components are particularly utilized for individuals experiencing both a disruptive cough and the presence of excess mucus, as seen in conditions like the common cold or bronchitis. This strategic combination of two agents sets it apart from single-ingredient preparations.

Composition and Pharmaceutical Form: Differentiating Factors

The active components are the antitussive Dextromethorphan and the expectorant Guaifenesin. Dextromethorphan is a synthetic derivative of levorphanol, while Guaifenesin is a synthetic derivative of guaiacol. The drug is specifically formulated as an elixir, a clear, sweetened oral solution intended for the oral route of administration. This liquid form is often favored over solid dosage forms, making it particularly suitable for pediatric patients or adults who may have difficulty swallowing tablets, while still providing measured, reliable dosing. Clinical pharmacology principles support the efficacy of this combination in managing concurrent symptoms.

General Purpose of the Dual-Action Formula

The integrated purpose of the formulation is directly linked to the distinct physiological actions of its components. Dextromethorphan acts centrally to suppress the cough reflex, which helps to reduce the frequency and intensity of coughing. Concurrently, Guaifenesin works peripherally as an expectorant by increasing the volume and reducing the viscosity of secretions in the airways. This action assists the body in the effective removal of phlegm and supports natural clearance. Research confirms that Guaifenesin is an effective agent for loosening phlegm and thinning bronchial secretions, confirming the medicine is designed to support the body’s process for clearing chest congestion while minimizing the disruptive urge to cough.

Regulatory References

  1. Dextromethorphan Guaifenesin - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Guaifenesin DM Elixir?

Adverse Reaction Scope

Commonly reported side effects involve the central nervous system (CNS) and gastrointestinal system, including dizziness, drowsiness, insomnia, and feelings of nervousness or restlessness. Gastrointestinal effects may include nausea, vomiting, abdominal discomfort, and diarrhea.

Serious and clinically significant adverse reactions are rare but include severe allergic reactions (e.g., hives, rash, swelling of the face, tongue, or throat) that require emergency medical attention. Other serious effects that warrant immediate professional consultation include mood changes, severe headache, and severe dizziness or anxiety.

Safety Restrictions and Population Considerations

Contraindications: This medication must not be used concurrently with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI). This restriction is critical due to the risk of a dangerous drug interaction known as Serotonin Syndrome.

Special Population Notes: Use of combination cough and cold products in very young children (typically under 4 years of age) has been associated with serious or life-threatening side effects, and caution is advised for the pediatric population. Certain liquid formulations may contain phenylalanine (a source of aspartame) and should be used with caution by individuals with phenylketonuria (PKU). The safety for use during pregnancy and breastfeeding is not fully established; use should be considered only when benefits outweigh potential risks.

Safety Monitoring: Avoid operating heavy machinery or driving until the effects of the medication are known, as it may cause drowsiness or dizziness. Guaifenesin may interfere with the results of certain laboratory tests, such as those for VMA and 5-HIAA.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states that an overdose involving Guaifenesin DM Elixir is a serious event requiring immediate action. The potential clinical manifestations primarily involve the central nervous system (CNS) and respiratory function.

System Clinical Manifestations (Regulatory-listed)
CNS Drowsiness, confusion, agitation, hallucinations, seizures, or progression to coma.
Respiratory Shallow breathing, difficulty breathing, or the cessation of breathing (apnea), especially noted in young children.
Cardiovascular Rapid heartbeat (tachycardia) and fluctuations in blood pressure.

Immediate medical attention must be sought right away in all cases of suspected overdose. Specific regulatory guidance dictates that emergency services (e.g., 911) must be contacted if the affected individual has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened. Contacting a certified Poison Control Center is also required.

The most severe documented outcomes include life-threatening Serotonin Syndrome (when taken with other serotonergic agents) and profound respiratory depression. Management is primarily symptomatic and supportive, and official prescribing information confirms that no specific antidote is known.

Advertisements

Therapeutic Uses of Guaifenesin DM Elixir

What Guaifenesin DM Elixir Treats: Main Uses and Benefits

This combination product is generally applied across therapeutic domains that involve symptomatic discomfort from conditions associated with acute or disruptive episodes, such as the common cold and flu. The elixir is used to provide supportive relief for symptoms related to the presence of both a persistent, disruptive cough and thick chest mucus.


The combination is commonly used across conditions characterized by periods of heightened symptoms where both cough irritation and mucus accumulation are present, relevant when short-term symptomatic assistance is needed.

“It helps address symptom clusters that may become intense or disruptive.”

This dual-action approach is used to provide support that helps ease the overall symptom burden, and contributes to easing discomfort during periods of heightened symptoms. It is applicable for conditions presenting with acute episodes of cough irritation, heavy chest mucus, and chest congestion.

Quick Fact: Dual Symptom Support
Used to help manage symptoms associated with: Persistent cough and thick, tenacious phlegm.
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and Cannot Use Guaifenesin DM Elixir

The eligibility profile for the Dextromethorphan and Guaifenesin combination elixir is defined by official regulatory criteria outlining absolute prohibitions and specific age-related and condition-based restrictions.


Absolute Contraindications

Category Exclusion Rule
Concurrent Medications Patients receiving or who have stopped Monoamine Oxidase Inhibitor (MAOI) therapy within the past 14 days.
Allergy Patients with known hypersensitivity to Dextromethorphan, Guaifenesin, or any component of the formulation.

Age and Conditional Restrictions

Category Regulatory Status
Approved Age Group Generally approved for Adults and Children 12 years of age and older.
Pediatric Restriction Use is not established for children under 2 years. Children under 4 years are generally not recommended to use OTC cough and cold medicines.
Chronic Cough Use is restricted for a persistent or chronic cough (e.g., associated with smoking or emphysema) unless it is also accompanied by excessive phlegm.
Physiological Status Use during pregnancy and lactation requires caution, and the medicine should only be administered if clearly needed, due to limited human data.

These rules establish the formal population boundaries for which the medicine is officially intended or strictly prohibited, as documented in governmental prescribing information.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation outlines specific interaction constraints and prohibitions for the active ingredients in Guaifenesin DM Elixir.

Contraindicated and High-Risk Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), such as Isocarboxazid, Linezolid, and Phenelzine, is strictly contraindicated. This prohibition is due to the high risk of a serious adverse reaction known as Serotonin Syndrome caused by additive central serotonergic effects. Administration must be separated by a mandatory 14-day window following the discontinuation of MAOI therapy.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance/Class Documented Regulatory Outcome
Pharmacokinetic (Exposure) Strong CYP2D6 Inhibitors (e.g., Quinidine) Increased systemic exposure (C max and AUC) of the Dextromethorphan component due to inhibition of its metabolism.
Pharmacodynamic (CNS Risk) CNS Depressants (including Alcohol) Potential for additive CNS depressant effects.
Pharmacodynamic (Serotonin Risk) Other Serotonergic Agents Increased risk of Serotonin Syndrome.

Laboratory Test Interference

The Guaifenesin component is documented to interfere with the colorimetric determination of certain urinary compounds, including 5-hydroxyindoleacetic acid (5-HIAA) and Vanillylmandelic acid (VMA). This interference can result in false positive analytical findings.

Advertisements

Mechanism of Action

How Guaifenesin DM Elixir Works

Modulation of Airway Secretions

This mechanistic domain is governed by guaifenesin, which acts to promote the release of fluid into the airways by stimulating secretory glands via a reflex arc. This action alters the physical properties of the respiratory content, specifically decreasing viscosity and surface tension, to support the body's physiological process of mucociliary transport.

Central Inhibition of the Cough Reflex

The second primary domain involves the action of dextromethorphan on the medullary cough center in the brain, primarily through Sigma-1 receptor (sigma1R) agonism. This mechanism elevates the neural threshold required to initiate a cough, resulting in a reduced excitability of the central cough reflex arc and diminished reflex frequency.

Combined Systemic and Local Actions

The overall physiological effect arises from the concurrent action of the two active ingredients on separate systems: peripheral secretion dynamics and central neural signaling. This mechanism engages two distinct pathways, resulting in the alteration of secretion viscosity and a simultaneous elevation of the cough reflex threshold.

Advertisements

Dosage and Administration Information

Guaifenesin DM Elixir is a combination liquid product intended solely for oral administration. The usage protocol is structured around the precise intake of a measured volume at specific intervals. Standard labeled dosing for adults and children 12 years of age and older is typically 10 mL to 20 mL of the liquid, depending on the specific product concentration. The regimen is designated for intermittent use and is to be taken every 4 hours as needed, with a strict limit not to exceed 6 doses within any 24-hour period. The maximum daily use of Guaifenesin from all sources should not exceed 2,400 mg.

To ensure dosing accuracy, official instructions mandate that the liquid must be measured only with a calibrated device or dosing cup provided with the elixir. The elixir can be taken without regard to food. Due to its expectorant component, the protocol is generally associated with the contextual use of maintaining adequate fluid intake. Specific population-based use is addressed by providing explicit dose reductions for pediatric patients in the 6 to under 12 years age group. If a dose is missed, the individual should skip the missed dose and resume the regular schedule, rather than taking a double quantity. The product is intended only for short-term, temporary administration.

Advertisements

Recent Clinical Evidence

Evidence for the Antitussive Component: Dextromethorphan

Research exploring Dextromethorphan, the component evaluated in studies measuring cough outcomes, has been conducted primarily through randomized controlled trials (RCTs). These studies typically apply to adults and adolescents experiencing acute cough associated with respiratory conditions. Researchers examined specific outcomes, measuring changes in cough frequency and cough severity over defined, short time intervals. Research highlights changes measured during the study period, with findings often described as varied. Some reviews note that evidence is mixed, showing both instances where patterns suggest a difference from placebo and instances where differences were minimal or non-significant.

Evidence for the Expectorant Component: Guaifenesin

Research exploring Guaifenesin, the component evaluated in studies measuring mucus outcomes, has focused on acute symptoms linked to excess bronchial secretions and chest congestion. Studies explored various outcomes, including objective measures of sputum thickness and volume, alongside patient-reported outcomes describing perceived ability to clear secretions. Evidence consistency for this component is described as variable across trials. While some studies reported measurements related to changes in sputum properties, other trials showed less clear results. The existing studies primarily reflect short-term observations, and certainty remains low regarding objective changes in phlegm characteristics.

Regulatory Basis and Evidence Gaps

Regulatory approval for the specific combination liquid formulation relies on PK (pharmacokinetic) and bioequivalence studies. These studies examined outcomes related to the absorption and clearance of both components when administered together in the elixir. Research describes that the combination formulation was associated with comparable absorption characteristics to those of the individual reference products. This research provides a regulatory foundation but does not assess the symptomatic effects of the two ingredients working together.

Long-term effects are not fully established because follow-up durations were generally limited across the primary clinical trials. Data for certain groups, particularly children under 12 years and individuals with pre-existing comorbid conditions, remain insufficient to fully characterize outcomes in these populations.

Key Studies & References Guaifenesin Syrup and Dextromethorphan - DailyMed (FDA-regulated Product Information)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Guaifenesin DM Elixir (FAQ)


Q: Is Guaifenesin DM Elixir the same as other cough syrups?

A: Official product information describes Guaifenesin DM Elixir as a combination product. It contains two active ingredients: an expectorant (guaifenesin) to loosen phlegm and a cough suppressant (dextromethorphan) to reduce the cough reflex. This dual-ingredient formulation makes it distinct from many single-ingredient cough syrups.


Q: Why is the drug described as an 'elixir'?

A: In pharmaceutical descriptions, an 'elixir' refers to the specific dosage form. It means the medicine is a clear, sweetened liquid preparation intended for oral use, which is a particular type of oral solution.


Q: How quickly does Guaifenesin DM Elixir usually start to work?

A: Based on information regarding the active ingredients, the expectorant component (guaifenesin) typically begins to show its effects approximately 30 minutes after being administered. The onset time for the cough suppressant component is also typically within the first hour of administration.


Q: How long do the effects of Guaifenesin DM Elixir typically last?

A: The formulation is directed to be taken every four hours as needed, according to official instructions. This interval is specified in official instructions and provides a guide for the maximum duration between doses.


Q: Does Guaifenesin DM Elixir contain alcohol?

A: Official product labeling for many formulations of Guaifenesin DM liquid specifically designates the product as Alcohol Free. Product information advises patients to check the inactive ingredients on the label of the specific product they are using.


Q: Are there any common foods or drinks that should be avoided when using this medicine?

A: Regulatory documentation specifically warns about the potential for additive CNS depressant effects when the medicine is combined with alcohol. No specific warnings regarding common foods are noted in the official interaction documents.


Q: What are the inactive ingredients in Guaifenesin DM Elixir?

A: Official product labeling lists ingredients that are not medically active. These can include purified water, various flavorings, sweeteners, colorants, and preservatives necessary to form the liquid and ensure stability. The specific list varies by manufacturer and formulation.


Q: Is there any research on the safety of Guaifenesin DM Elixir for older adults?

A: Specific clinical trial data for older adults may be limited. However, official regulatory reviews suggest that guaifenesin use in older adults is not associated with unique side effects compared to younger adults.


Q: Can a person with diabetes use a liquid medicine like Guaifenesin DM Elixir?

A: Official product labeling must list the presence of any sucrose or other sugars, or state if the formulation is sugar-free. For individuals managing blood sugar, information about sweeteners is available in the inactive ingredients section on the product label.


Q: What are the signs that Guaifenesin DM Elixir may not be working?

A: Official documents advise discontinuing use and seeking consultation if the cough lasts more than 7 days, if it returns, or if it is accompanied by fever, rash, or persistent headache. These criteria are intended to guide a person toward seeking consultation, as symptoms lasting longer than 7 days may indicate a more serious condition.


Q: Is it normal to notice a change in the color or consistency of mucus after using the drug?

A: The expectorant component, guaifenesin, works by actively thinning and loosening mucus in the airways. This action supports the body's clearance process and may result in a perceived change in the consistency of phlegm.


Q: Are there official warnings about combining Guaifenesin DM Elixir with herbal supplements?

A: While regulatory warnings focus mainly on prescription drugs like MAOIs, official regulatory guidance advises providing information to a healthcare provider about all medicines and supplements, including herbal products, that are being used.


Q: Is the sensation of feeling lightheaded sometimes associated with Guaifenesin DM Elixir?

A: Official documents list dizziness as a common side effect associated with the use of the drug. Because of the possibility of dizziness, official safety information recommends avoiding activities that require alertness, such as driving or operating heavy machinery.


Q: Does the medicine come in different strengths or flavors?

A: The medication is available in different liquid strengths and may be offered in various flavors (e.g., cherry or raspberry). This is noted in the official 'How Supplied' sections of the drug information.


Q: Are there certain medications that contain the same active ingredients as Guaifenesin DM Elixir?

A: Yes, many non-prescription cough and cold products contain the same active ingredients: guaifenesin and dextromethorphan. The labeling advises patients to verify the ingredients of other cold and cough medicines to ensure they do not exceed the maximum recommended daily amount of either active component.


Q: Do people commonly misuse or overuse Guaifenesin DM Elixir?

A: Regulatory warnings specifically caution against increasing the dose or taking the medicine more often or for a longer time than directed, citing the risk of improper use or abuse. The medication should be used strictly as directed on the label.


Q: What is the significance of the syrup's color or clarity?

A: The drug is described in official documents as a clear liquid that may be colored (e.g., reddish), as part of its physical description. This allows consumers to verify that the appearance of the product matches the official description.


Q: Are there any specific patient groups who should be monitored closely when using this drug?

A: Official labeling advises seeking consultation before use for individuals with specific pre-existing conditions, such as chronic cough associated with smoking or asthma, or a history of liver problems.


Q: Can Guaifenesin DM Elixir affect the results of certain medical tests?

A: The guaifenesin component is documented to interfere with certain laboratory tests used to measure compounds in the urine, such as VMA and 5-HIAA. The labeling advises patients to notify the appropriate personnel about the use of this drug before having certain laboratory tests.


Q: Why do official documents caution against using this drug for a long period?

A: The drug is intended only for short-term, temporary use. Official warnings advise seeking professional consultation if the cough persists longer than 7 days. This is because a long-lasting cough could be a sign of a more serious underlying medical condition.


Q: Can the medicine be used if a person has a fever alongside the cough?

A: The official labeling states that if the cough is accompanied by a fever, rash, or persistent headache, official guidance is to discontinue use and seek professional consultation, as these symptoms can indicate a more serious condition.


Q: Why is this drug sometimes used for non-cough related conditions?

A: Official regulatory documents define the product's approved use solely as the temporary relief of cough and to loosen phlegm. The label does not mention or support any use for conditions outside of those related to acute respiratory symptoms.

Advertisements

How should Guaifenesin DM Elixir be stored and disposed of?

Storage and Disposal Requirements

Guaifenesin DM Elixir must be stored according to official regulatory guidelines to maintain its stability. The product is required to be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Storage areas must protect the elixir from light, excessive heat, and moisture. The official labeling explicitly states Do not freeze and Do not refrigerate.

To ensure integrity, the container must be kept tightly closed in its original packaging and must not be used past the expiration date. It is a mandatory requirement to store the medication out of the sight and reach of children.

Disposal of any unused or expired product must be done properly by following local regulations. The medicine should not be poured down any drain or flushed down the toilet unless specific instructions from a federal or local authority permit this action.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Guaifenesin DM Elixir found in:

A-Z Index: